The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway.

Yujian Dai, Huiming Zheng, Zhen Liu, Yingjun Wang, Weize Hu

Investigational new drugs 2021 Jun

filter terms:

Infantile hemangioma is the most common vascular tumor of childhood. It is characterized by clinical expansion of endothelial cells and promoted by angiogenic factors. Luteolin is a flavonoid compound that carries anti-cancer and anti-angiogenesis properties. The study aimed to investigate the effect of luteolin in treating infantile hemangioma. We first tested the effect of luteolin on cell proliferative potential and VEGFA expression in hemangioma-derived stem cells (HemSCs). We then examined the efficacy of systemic application of luteolin in a murine hemangioma model. We then identified the downstream factor regulated by luteolin in HemSCs and validated its causative relationship with knock-down method in both in vitro and in vivo models. We also investigated the protein expression change of this targeting factor in proliferating hemangiomas. Luteolin inhibited HemSC growth and suppressed VEGF-A expression in a dose-dependent manner. Luteolin inhibited microvessel formation and de novo vasculogenesis in the murine model. FZD6 was induced by luteolin and exerted the anti-angiogenesis effect in our tumor models. Lastly, FZD6 level was repressed in the clinical tissues of human proliferating hemangiomas. Luteolin is a promising new agent to treat infantile hemangioma. Targeting the Wnt pathway may represent a potential therapeutic strategic to inhibit angiogenesis in proliferating hemangiomas.

Citation

Yujian Dai, Huiming Zheng, Zhen Liu, Yingjun Wang, Weize Hu. The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway. Investigational new drugs. 2021 Jun;39(3):775-784